
A peptide CDMO quality agreement should assign each quality decision to a named party and identify the records that support it. Before signing, settle who approves specifications, who authorizes changes, how a disputed result is investigated, and who decides whether a batch can be supplied. An order confirmation rarely answers all of those questions.
OEM, ODM, CRO and CDMO describe different commercial arrangements. Their boundaries vary between suppliers. Use the agreed deliverables and decision rights to define the relationship, especially when development, testing and packaging involve different organizations.
Separate commercial terms from quality decisions
The purchase agreement can cover price, payment, intellectual property and delivery. A quality agreement records how the parties handle product quality during that relationship. The documents should refer to compatible specifications and avoid assigning the same decision to two different people.
FDA’s November 2016 guidance on contract manufacturing quality agreements concerns drug manufacturing subject to CGMP. It explains how owners and contract facilities can document their respective manufacturing activities. That pharmaceutical scope matters: citing the guidance does not establish that a cosmetic ingredient or research material is a drug product, or that a supplier has a particular regulatory status.
Define the product covered by the agreement
List the exact material or product family, the relevant specification revision, the supply stage and the intended B2B use. A bulk peptide raw material, a lyophilized vial presentation and a branded finished format can require different records and approvals. Identify any laboratory or packaging contractor whose work is part of the supplied output.
Build a responsibility matrix around actual decisions
The following is a suggested discussion matrix. It is a procurement aid, not a statement of how every CDMO works. Replace role names with the parties and contacts in the proposed project.
| Decision or record | Responsibility to settle | Evidence to retain |
|---|---|---|
| Specification approval | Who prepares, reviews and authorizes the version used for the order? | Approved specification with revision and effective date |
| External testing | Who selects the laboratory, sends samples and receives complete reports? | Laboratory identity, test scope and sample linkage |
| Batch disposition | Who makes the supplier’s release decision and the buyer’s incoming acceptance decision? | Separate release and receiving records where applicable |
| Changes | Which changes require notification or approval before implementation? | Change assessment, approvals and implementation record |
| Disputed results | Who leads the investigation and approves further work? | Investigation record, conclusions and agreed disposition |
| Complaints and records | Who can retrieve records and answer a quality complaint? | Named contact, access arrangements and retention terms |
A useful matrix distinguishes performing a task from approving its outcome. For example, the laboratory may issue a test report while the manufacturer’s authorized quality function makes a release decision. The buyer may then conduct its own incoming review. Write those as separate activities.
Agree how exceptions will be handled
A result outside the agreed specification
Ask how a result is communicated, which records become available, and who can authorize additional investigation. Specify how the original result remains linked to any later result. Avoid an arrangement in which an updated certificate silently replaces the history of the batch.
FDA’s December 2018 data-integrity guidance addresses reliable and accurate data in drug CGMP operations. For procurement, a practical question is whether the report, its revision history and the underlying sample identification can be retrieved together.
A proposed material, method or packaging change
Define the changes that require a buyer’s review. Examples to discuss include a manufacturing site change, an analytical method revision or a different product-contact container. Do not put an arbitrary universal notification period into every agreement. Agree a period and escalation route that suit the decision and the available evidence.
ICH Q10 describes pharmaceutical quality management across the product lifecycle. Its change-management framework is a useful reference when discussing assessment, approval and follow-up. The formality and applicable requirements still depend on the project.
Check the agreement against one realistic scenario
Try a short tabletop review before signature. Suppose a packaging component becomes unavailable after the buyer has approved the artwork. Can the team identify who assesses the alternative component, which specification is affected, who authorizes the change and what happens to the shipment date?
If the answer depends on finding an old email, add the missing responsibility or record reference. This exercise usually reveals ambiguous ownership more quickly than another round of general assurances.
- Match product names and document revisions across the agreement and quotation.
- Record who owns the technical dossier and how access works after the project ends.
- Confirm the route for urgent quality communication, including an unavailable primary contact.
- Resolve conflicting release, acceptance or subcontracting language before production is committed.
For a Hytanbio peptide CDMO project, include the proposed quality responsibilities with the initial brief. If the work also involves an outside site or a transferred specification, use the technology-transfer dossier checklist to define the handover.
Frequently asked questions
Does a peptide CDMO quality agreement replace a purchase agreement?
It usually has a different purpose. The purchase agreement records commercial obligations, while the quality agreement assigns quality activities and decision rights. Check that the two documents use compatible specifications and responsibilities.
Who should release a peptide batch?
Identify the supplier's authorized release function and the buyer's incoming acceptance function in the project documents. The testing laboratory, manufacturer and buyer can have different responsibilities; the agreement should state each one.
Does citing FDA's quality-agreement guidance prove that a peptide product is approved?
No. The guidance concerns responsibilities in drug contract manufacturing under its stated CGMP scope. A citation does not establish the regulatory status, approval or suitability of a particular supplier or product.
What should happen if a proposed packaging component changes?
Use the agreed change process to identify the affected specification, assess the supporting evidence and obtain the required approvals. Record the decision before making a commitment that depends on the revised component.
References and scope
- FDA: Contract Manufacturing Arrangements for Drugs: Quality Agreements, final guidance, November 2016.
- FDA: Data Integrity and Compliance With Drug CGMP, final guidance, December 2018.
- EMA: ICH Q10 Pharmaceutical quality system.
These pharmaceutical references provide context for project discussions. Applicability must be established for the actual product, activity and destination market.
Prepared by the Hytanbio Technical Editorial Team for B2B project planning. Company-specific information is based on supplied company materials. Project specifications and documentation must be confirmed for the requested product and intended market.